Cargando…

Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications [Corrigendum]

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6103613/ https://www.ncbi.nlm.nih.gov/pubmed/30154643 http://dx.doi.org/10.2147/OPTH.S179994

Ejemplares similares

Ocular pharmacokinetics and tolerability of bimatoprost ophthalmic solutions administered once or twice daily in rabbits, and clinical dosing implications
por: Shen, Jie, et al.
Publicado: (2017)

Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes
por: Shafiee, Afshin, et al.
Publicado: (2013)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. [Corrigendum]
Publicado: (2013)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events [Corrigendum]
Publicado: (2013)

Patient considerations in ocular hypertension: role of bimatoprost ophthalmic solution
por: Lee, Daniel, et al.
Publicado: (2017)

Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD [Corrigendum]
Publicado: (2014)

The Effect of Orally Administered Ranitidine and Once‐Daily or Twice‐Daily Orally Administered Omeprazole on Intragastric pH in Cats
por: Šutalo, S., et al.
Publicado: (2015)

Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial [Corrigendum]
Publicado: (2018)

Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial
por: Day, Douglas G, et al.
Publicado: (2013)

Efficacy and safety of fixed-combination bimatoprost/timolol ophthalmic solution
por: Moon, Suk Bae, et al.
Publicado: (2017)

Pharmacokinetics and safety after once and twice a day doses of meclizine hydrochloride administered to children with achondroplasia
por: Kitoh, Hiroshi, et al.
Publicado: (2020)

Effect of Solution pH on Distribution of Ophthalmically Administered Brimonidine in Posterior Ocular Tissues in Pigmented Rabbits
por: Shinno, Keisuke, et al.
Publicado: (2019)

Corrigendum to “Relationship between the Direction of Ophthalmic Artery Blood Flow and Ocular Microcirculation before and after Carotid Artery Stenting”
por: Ishii, Masashi, et al.
Publicado: (2017)

Once– versus twice–daily tacrolimus: are the formulations equivalent?
por: Ciszek, Michał
Publicado: (2013)

Preservative-Free versus Benzalkonium Chloride–Preserved Latanoprost Ophthalmic Solution in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Phase 3 US Clinical Trial [Corrigendum]
Publicado: (2023)

Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study
por: Church, Alison, et al.
Publicado: (2014)

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide
por: Astrup, A, et al.
Publicado: (2012)

Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial
por: Goldberg, Ivan, et al.
Publicado: (2014)

Pharmacokinetics and Safety of a Bilastine Once-Daily, Preservative-Free, Ophthalmic Formulation
por: Ochoa, Dolores, et al.
Publicado: (2021)

Pharmacokinetics of Once‐Daily Extended‐Release Tacrolimus Tablets Versus Twice‐Daily Capsules in De Novo Liver Transplant
por: DuBay, Derek A., et al.
Publicado: (2019)

Pharmacokinetic (PK) and pharmacodynamic analyses of once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial
por: Sekar, V, et al.
Publicado: (2010)

Conversion from twice- to once-daily tacrolimus in pediatric kidney recipients: a pharmacokinetic and bioequivalence study
por: Lapeyraque, Anne-Laure, et al.
Publicado: (2014)

Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study [Corrigendum]
Publicado: (2015)

Pharmacodynamics and Pharmacokinetics Following Once-Daily and Twice-Daily Dosing of Tiotropium Respimat(®) in Asthma Using Standardized Sample-Contamination Avoidance
por: Beeh, Kai-Michael, et al.
Publicado: (2016)

Efficacy and Safety of Retinol Palmitate Ophthalmic Solution in the Treatment of Dry Eye: A Japanese Phase II Clinical Trial [Corrigendum]
Publicado: (2021)

Is once enough? Understanding the preferences of COPD and asthma patients for once- versus twice-daily treatment
por: Horne, Rob
Publicado: (2013)

Corrigendum to “Utility of Experimental Design in Pre-Column Derivatization for the Analysis of Tobramycin by HPLC—Fluorescence Detection: Application to Ophthalmic Solution and Human Plasma”
por: El-Zaher, Asmaa A, et al.
Publicado: (2014)

Comparison of once daily versus twice daily olmesartan in patients with chronic kidney disease
por: Sakai, Yukinao, et al.
Publicado: (2013)

The Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide 400 μg Administered by Inhalation as Single and Multiple (Twice Daily) Doses in Healthy Chinese Participants
por: Li, Weimin, et al.
Publicado: (2023)

Corrigendum to “Pulsed Radiofrequency of the Trigeminal Ganglion for Treating Postherpetic Neuralgia of the Ophthalmic Branch”
por: Liu, Dong-Yang, et al.
Publicado: (2021)

Once‐ and twice‐daily heat acclimation confer similar heat adaptations, inflammatory responses and exercise tolerance improvements
por: Willmott, Ashley G. B., et al.
Publicado: (2018)

Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma
por: Woodcock, Ashley, et al.
Publicado: (2011)

Comparison of once-daily versus twice-daily combination of Ropinirole prolonged release in Parkinson’s disease
por: Yun, Ji Young, et al.
Publicado: (2013)

Effects of Converting Tacrolimus Formulation from Twice-Daily to Once-Daily in Liver Transplantation Recipients
por: Thorat, Ashok, et al.
Publicado: (2014)

Twice-Daily versus Once-Daily Pramipexole Extended Release Dosage Regimens in Parkinson's Disease
por: Yun, Ji Young, et al.
Publicado: (2017)

Twice-daily versus once-daily lisinopril and losartan for hypertension: Real-world effectiveness and safety
por: Derington, Catherine G., et al.
Publicado: (2020)

Efficacy and safety of once daily tacrolimus compared to twice daily tacrolimus after liver transplantation
por: Bzeizi, Khalid Ibrahim, et al.
Publicado: (2021)

A randomized trial of once daily versus twice daily dosing of oral iron in CKD
por: Sood, Vivek, et al.
Publicado: (2023)

Measure Twice, Cut Once
por: D’Alessandro, David A., et al.
Publicado: (2021)

Once vs. twice-daily lopinavir/ritonavir in HIV-1-infected children
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_oa0tglsa013pu4pb9ebutqciht